AUTHOR=Yamauchi Junji , Cizik Amy M. , Fornadi Katalin , Thomas Dominik , Raghavan Divya , Jweehan Duha , Oygen Suayp , Marineci Silviana , Buff Michelle , Selim Motaz , Zimmerman Michael , Mucsi Istvan , Molnar Miklos Z. 

TITLE=Associations of Pretransplant Patient-Reported Outcomes Measurement Information System Physical Function Score With Kidney Transplant Outcomes

JOURNAL=Transplant International

VOLUME=Volume 38 - 2025

YEAR=2025

URL=https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.13884

DOI=10.3389/ti.2025.13884

ISSN=1432-2277

ABSTRACT=Simple and validated physical function measures for daily clinical use are needed for kidney transplant candidates because pretransplant low physical function is a common and potentially modifiable risk factor for poor transplant outcomes. This single-center retrospective study aimed to investigate the associations between pretransplant physical function assessed by the Patient-Reported Outcomes Measurement Information System® Physical Function (PROMIS-PF) and early posttransplant outcomes. PROMIS-PF was administered using computer adaptive testing and scored using the T-score metric. We analyzed 154 adult kidney-alone transplant recipients. The median pretransplant PROMIS-PF score was 43 (interquartile range, 39-47). Patient characteristics were not significantly different across PROMIS-PF score quartiles. The pretransplant PROMIS-PF score was not associated with length of transplant hospital stay, delayed graft function, 6-month and 12-month graft function, or 12-month patient and graft survival. Trend tests and adjusted logistic regression analyses demonstrated that a lower pretransplant PROMIS-PF score was significantly associated with a higher risk of emergency room visits and rehospitalization within 1 month posttransplant (p for trend=0.025 and 0.044, respectively). Results suggest that PROMIS-PF is a promising and practical tool for assessing physical function in kidney transplant candidates. Larger studies are needed to confirm the utility of using PROMIS-PF to prehabilitate patients in this population.